Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Novembro 2023 - 7:15PM
Business Wire
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the
“Company”) today announced that it has granted stock options and
restricted stock units (“RSUs”) to Camille L. Bedrosian, MD, the
Company’s newly appointed Chief Medical Officer. The Compensation
Committee of Amylyx’ Board of Directors approved the grant,
effective November 27, 2023, to Dr. Bedrosian of non-qualified
stock option awards to purchase up to 162,500 shares of the
Company's common stock and 58,333 RSUs under the Amylyx
Pharmaceuticals, Inc. 2023 Inducement Plan (“2023 Inducement
Plan”). The awards were granted as an inducement material to Dr.
Bedrosian entering into employment with Amylyx in accordance with
Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $12.93 per share, which is
equal to the closing price of Amylyx' common stock as reported by
The Nasdaq Global Select Market on November 27, 2023. The options
have a ten-year term and will vest over four years, with 25%
vesting on the one-year anniversary of the applicable vesting
commencement date and the remaining 75% vesting in a series of 36
successive monthly installments thereafter, subject Dr. Bedrosian’s
continued employment with Amylyx on such vesting dates. The RSUs
will vest in four installments on the first four anniversaries of
the applicable vesting commencement date, subject to Dr.
Bedrosian’s continued employment with Amylyx on such vesting dates.
The awards are subject to the terms and conditions of the 2023
Inducement Plan.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is committed to supporting and
creating more moments for the neurodegenerative community through
the discovery and development of innovative new treatments. Amylyx
is headquartered in Cambridge, Massachusetts and has operations in
Canada and EMEA. For more information, visit amylyx.com and follow
us on LinkedIn and X, formerly known as Twitter. For investors,
please visit investors.amylyx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231129035056/en/
Media Amylyx Media Team +1 (857) 799-7274
amylyxmediateam@amylyx.com Investors Lindsey Allen Amylyx
Pharmaceuticals, Inc. +1 (857) 320-6244 Investors@amylyx.com
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024